Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:13 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT07484230 · Sanofi · PHASE3 · withdrawn · last registry update 2026-08-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision. Not related to safety concern.” | – | Registry record, Sanofi |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL33 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-15Results posted on the registry: Sanofi, Itepekimab SAR440340 + Placebo (NCT04701983)
- 2026-10-09Results posted on the registry: Sanofi, Itepekimab SAR440340 + Placebo (NCT04751487)
- 2026-10-07Results posted on the registry: Sanofi, Itepekimab (SAR440340) + Placebo (NCT06280391)
- 2026-08-31Results posted on the registry: Sanofi, Itepekimab SAR440340 (NCT05326412)
- 2026-02-20Phase 3 first posted: Sanofi, Itepekimab (SAR440340) + Placebo (NCT07424144)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision